Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells - PubMed (original) (raw)
Affiliations
- PMID: 7911565
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
R J Pietras et al. Oncogene. 1994 Jul.
Abstract
Approximately 30% of human breast and ovarian cancers have amplification and/or overexpression of HER-2/neu gene which encodes a cell surface growth-factor receptor. Overexpression of this receptor, p185HER-2/neu, is associated with poor outcome and may predict clinical response to chemotherapy. Antibodies to HER-2/neu receptor have a cytostatic effect in suppressing growth of cells with overexpression of p185HER-2/neu. To elicit a cytocidal effect, therapy with antireceptor antibody was used in combination with the DNA-damaging drug, cisplatin, and this combined treatment produced a synergistic decrease in cell growth. In addition, antibody mediated an increased sensitivity to cisplatin in drug-resistant ovarian carcinoma cells containing multiple copies of HER-2/neu gene. To evaluate the mechanism for this synergy, unscheduled DNA synthesis was measured in cancer cells using incorporation of [3H]thymidine and autoradiography, and formation and repair of cisplatin-induced DNA adducts was also measured. Treatment with cisplatin led to a marked, dose-dependent increase in unscheduled DNA synthesis which was significantly reduced by combined treatment with antireceptor antibody in HER-2/neu-overexpressing cells. Therapy with antibody to HER-2/neu receptor also led to a 35-40% reduction in repair of cisplatin-DNA adducts after cisplatin exposure and, as a result, promoted drug-induced killing in target cells. This phenomenon which we term receptor-enhanced chemosensitivity may provide a rationale for more selective targeting and exploitation of overexpressed growth factor receptors in cancer cells, thus leading to new strategies for clinical intervention.
Similar articles
- Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Pietras RJ, et al. Oncogene. 1998 Oct 29;17(17):2235-49. doi: 10.1038/sj.onc.1202132. Oncogene. 1998. PMID: 9811454 - The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD, Karlan BY. Cirisano FD, et al. J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105. J Soc Gynecol Investig. 1996. PMID: 8796816 Review. - The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS, Fletcher JA. Ross JS, et al. Stem Cells. 1998;16(6):413-28. doi: 10.1002/stem.160413. Stem Cells. 1998. PMID: 9831867 Review.
Cited by
- Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies.
Mo C, Sterpi M, Jeon H, Bteich F. Mo C, et al. Cancers (Basel). 2024 Aug 15;16(16):2854. doi: 10.3390/cancers16162854. Cancers (Basel). 2024. PMID: 39199625 Free PMC article. Review. - New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?
Scandurra G, Lombardo V, Scibilia G, Sambataro D, Gebbia V, Scollo P, Pecorino B, Valerio MR. Scandurra G, et al. Cancers (Basel). 2024 Jul 5;16(13):2466. doi: 10.3390/cancers16132466. Cancers (Basel). 2024. PMID: 39001528 Free PMC article. Review. - Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: A Bayesian network meta-analysis.
Li L, Wu Y, Lan B, Ma F. Li L, et al. Cancer Innov. 2024 May 22;3(4):e126. doi: 10.1002/cai2.126. eCollection 2024 Aug. Cancer Innov. 2024. PMID: 38948247 Free PMC article. - Twenty-five years with HER2 targeted therapy.
Jørgensen JT. Jørgensen JT. Ann Transl Med. 2024 Jun 10;12(3):53. doi: 10.21037/atm-23-153. Epub 2023 Jun 25. Ann Transl Med. 2024. PMID: 38911570 Free PMC article. Review. - HER2-targeted therapies in cancer: a systematic review.
Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. Zhu K, et al. Biomark Res. 2024 Feb 2;12(1):16. doi: 10.1186/s40364-024-00565-1. Biomark Res. 2024. PMID: 38308374 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous